News

The MGH Cancer Center and the Wellcome Trust Sanger Institute of the United Kingdom have begun a new alliance in cancer genome research.

Cancer genome research

09/Jan/2009

The MGH Cancer Center and the Wellcome Trust Sanger Institute of the United Kingdom have begun a new alliance in cancer genome research. The $13 million, five-year project will provide novel insights into genetic features of individual tumors that may determine their response to drug treatment.

Daniel Haber, left, and Jeffrey Settleman

Jeffrey Settleman, PhD, scientific director of the MGH Cancer Center, and his laboratory staff have amassed the largest collection of cancer tumor cell lines in the world -- more than 1,200. "This collaborative study will make use of our cell line repository to identify genomic features that underlie drug sensitivity," says Settleman. "Such information will be of tremendous value in informing the design of clinical trials for targeted, anti-cancer drugs that currently are being developed and for informing treatment decisions with existing cancer drugs." The project is co-led by Daniel Haber, MD, PhD, MGH Cancer Center director, and Michael Stratton, FRS, and Andy Futreal, MD, of the Wellcome Trust Sanger Institute.

Learn more about the Cancer Center

patient

U.S. News and World Report Best Hospitals 2013-2014

U.S. News & World Report ranks Mass General #2 in the nation and #1 in New England based on our quality of care, patient safety and reputation in 16 clinical specialties.

Search the Mass General news archive

Search the archive for previously published news articles, press releases and publications.

View all departments

Departments and Centers at Mass General have a reputation for excellence in patient care. View a list of all departments.